TISLELIZUMAB
Clinical trials for TISLELIZUMAB explained in plain language.
Never miss a new study
Get alerted when new TISLELIZUMAB trials appear
Sign up with your email to follow new studies for TISLELIZUMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to wipe out hidden cancer cells after chemo
Disease control Recruiting nowThis study tests whether two drugs, fruquintinib and tislelizumab, can control colorectal cancer in people who still have signs of cancer cells in their blood after finishing chemotherapy. About 20 adults with stable disease will receive the combination to see if it is safe and c…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:02 UTC
-
New triple therapy offers hope for advanced lung cancer patients
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a sequence of platinum-based chemotherapy, followed by a special type of radiation (hypofractionated radiotherapy), and then the immunotherapy…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Zibo Municipal Hospital • Aim: Disease control
Last updated May 26, 2026 04:02 UTC
-
New combo may treat kidney cancer without removing the organ
Disease control Recruiting nowThis study tests whether a combination of two drugs (tislelizumab and nab-paclitaxel) can treat renal pelvic cancer while avoiding removal of the kidney. About 35 adults with early-stage cancer that hasn't spread will receive the drugs, and if the tumor shrinks enough, they may g…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Gut bacteria may help shrink rectal tumors before surgery
Disease control Recruiting nowThis study tests whether adding a probiotic called Probio-M9 to standard chemoradiation and immunotherapy can help shrink tumors more effectively in people with locally advanced rectal cancer. About 50 adults with stage II or III rectal cancer will be randomly assigned to receive…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Seventh Medical Center of PLA General Hospital • Aim: Disease control
Last updated May 26, 2026 03:51 UTC